DEA Vs. White House: Agency Pushes Back On Medical Benefits Of Cannabis, Weed Stocks Wobble
Tension between the White House and the Drug Enforcement Administration (DEA) over marijuana rescheduling seems to be increasing, according to a Wall Street Journal report noting that some DEA officials are resisting this change on the basis that cannabis’ “medicinal benefits remain unproven and that it has a high potential for abuse, people familiar with the matter said.”
This is in contradiction to the Department of Health and Human Services (HHS) January release of 252 pages of documents stating that cannabis “has a currently accepted medical use in treatment in the United States” and a “potential for abuse less than the drugs or other substances in Schedules I and II.”
In addition to reportedly doubting the scientific evidence presented by HHS, the DEA also expressed concern about the increasing potency of THC, the …